1. Scrip
  2. >>Therapy Areas

Pharmamar: Yondelis and beyond

 
• By Francesca Bruce

The Spanish biotech company Pharmamar, has its sights set on expansion and has opened its first operations outside its home market in Italy. The firm's managing director, Luis Mora, spoke to Scrip about why Italy was a first good bet and what it plans to do beyond Yondelis (trabectedin), the only product it has so far brought to the market.

The Spanish biotech company Pharmamar, has its sights set on expansion and has opened its first operations outside its home market in Italy. The firm's managing director, Luis Mora, spoke to Scrip about why Italy was a first good bet and what it plans to do beyond Yondelis (trabectedin), the only product it has so far brought to the market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.